Spirometric reversibility to Salbutamol in chronic obstructive pulmonary disease (COPD). Differential effects on FEV 1 and on lung volumes;Reversibilidad espirométrica en la enfermedad pulmonar obstructiva crónica. Efecto diferencial del salbutamol sobre el volumen espiratorio forzado del primer segundo y el volumen pulmonar

Revista Medica de Chile

Volumn 132, Issue 7, 2004, Pages 787-793

  Manríquez H, Jorge ^a   Díaz P, Orlando ^a   Borzone T, Gisella ^a   Lisboa B, Carmen ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Bronchodilator agents; Pulmonary disease, chronic obstructive; Respiratory functions tests; Spirometry

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; SALBUTAMOL; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG INFLATION; LUNG VOLUME; MALE; PREDICTION; SINGLE DRUG DOSE; SPIROMETRY; TACHYCARDIA; TREMOR; VITAL CAPACITY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ALBUTEROL; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INSPIRATORY CAPACITY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 12344316711     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. AMERICAN THORACIC SOCIETY. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-18.
2. MORENO R, OYARZÚN M. Recomendaciones sobre informe espirométrico. Segunda parte. Enferm Respir Cir Tor 1988; 4: 136-49.
3. QUANJER PH, TAMMELING GJ, COTES JE, PEDERSEN OF, PESLIN R, YERNAULT JC. Lung volumes and forced ventilatory flows. Report of the working party: «Standardization of lung function tests». European Community for Steel and Coal. Eur Respir J 1993; 6 (Suppl 16): 5-40.
4. SIAFAKAS NM, VERMEIRE P, PRIDE NB, PAOLETTI P, GIBSON J, HOWARD P ET AL. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
5. GUYATT GH, TOWNSEND M, NOGRADI S, PUGSLEY SO, KELLER JL, NEWHOUSE MT. Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med 1988; 148: 1949-52.
6. ELTAYARA L, BECKLAKE MR, VOLTA CA, MILIC-EMILI J. Relationship between chronic dyspnea and expiratory ilow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 1726-34.
7. O'DONNELL DE, WEBB KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993; 148: 1351-7.
8. O'DONNELL, DE, REVILL SM, WEBB KA. Dynamic-hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7.
9. DIAZ O, VILLAFRANCA C, GHEZZO H, BORZONE G, LEIVA A, MILIC-EMILI J ET AL. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16: 269-75.
10. NEWTON MF, O'DONNELL DE, FORKERT L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-50.
11. HADCROFT J, CALVERLEY PMA. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56: 713-20.
12. O'DONNELL DE, FORKERT L, WEBB KA. Evaluation of bronchodilator responses in patients with «irreversible» emphysema. Eur Respir J 2001; 18: 914-20.
13. TANTUCCI C, DUGUET A, SIMILOWSKI T, ZELTER M, DERENNE J-P, MILIC-EMILI J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
14. BONI E, CORDA L, FRANCHINI D, CHIROLI P, DAMIANI GP, PINI L ET AL. Volume effect and exertional dyspnoea alter bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57: 528-32.
15. AMERICAN THORACIC SOCIETY STATEMENT. Standards for the diagnosis and care of patients with COPD. Am J Respir Crit Care Med 1995; 152: S78-S121.
16. AMERICAN THORACIC SOCIETY. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-30.
17. KNUDSON RJ, LEBOWIST MD, HOLBERG CI, BURROWS B. Changes in the normal expiratory flow-volume curve with growth and age. Am Rev Respir Dis 1983; 127: 725-34.
18. PAUWELS RA, BUIST AS, CALVERLEY PMA, JENKINS CR, HURD SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-70.
19. LISBOA C, BORZONE G, DÍAZ O. Hiperinflación pulmonar en La enfermedad pulmonar obstructiva crónica: Importancia funcional y clínica. Rev Chil Enf Respir 2004; 20: 9-20.
20. BELMAN MJ, BOTNICK WC, SHIN JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-75.
21. O'DONNELL DE, LAM M, WEBB KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-9.
22. DI MARCO F, MILIC-EMILI J, BOVERI B, CARLUCCI P, SANTUS P, CASANOVA F ET AL. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21: 86-94.
23. SOCIEDAD CHILENA DE ENFERMEDADES RESPIRATORIAS. Consenso nacional en enfermedad pulmonar obstructiva crónica (EPOC). Rev Chil Enf Respir 1998; 14: 69-82.
24. CERVERI I, PELLFGRINO R, DORE R, CORSICO A, FULGONI P, VAN DE WOESTIJNE P ET AL. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88: 1989-95.